Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New Treatment Schedule With Improved Survival in Childhood Leukemia

New Treatment Schedule With Improved Survival in Childhood Leukemia Folic acid antagonists were introduced for the treatment of acute leukemia in 1948 by Farber and his associates.1 Early experience with parenteral administration of folic acid analogues was thought to show no advantage over oral administration. Methotrexate evolved as the most commonly used compound. The drug was usually given in daily oral doses of 1 to 5 mg, depending on the age of the patient. Complete remissions were induced in 11 of 48 previously untreated children with acute lymphocytic leukemia and lasted for a median of 17 weeks in a previous study conducted by members of the Acute Leukemia Group B.2 (The diagnosis, as used by the authors, includes stem cell leukemia but excludes acute myelocytic leukemia.) Other authors achieved comparable results. Goldin et al explored the effect of different dose schedules of methotrexate on the survival of mice with leukemia 1210.3 Drug administration every fourth day http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

New Treatment Schedule With Improved Survival in Childhood Leukemia

,
JAMA , Volume 194 (1) – Oct 4, 1965

Loading next page...
 
/lp/american-medical-association/new-treatment-schedule-with-improved-survival-in-childhood-leukemia-Rw9nQzzv0B
Publisher
American Medical Association
Copyright
Copyright © 1965 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1965.03090140083021
Publisher site
See Article on Publisher Site

Abstract

Folic acid antagonists were introduced for the treatment of acute leukemia in 1948 by Farber and his associates.1 Early experience with parenteral administration of folic acid analogues was thought to show no advantage over oral administration. Methotrexate evolved as the most commonly used compound. The drug was usually given in daily oral doses of 1 to 5 mg, depending on the age of the patient. Complete remissions were induced in 11 of 48 previously untreated children with acute lymphocytic leukemia and lasted for a median of 17 weeks in a previous study conducted by members of the Acute Leukemia Group B.2 (The diagnosis, as used by the authors, includes stem cell leukemia but excludes acute myelocytic leukemia.) Other authors achieved comparable results. Goldin et al explored the effect of different dose schedules of methotrexate on the survival of mice with leukemia 1210.3 Drug administration every fourth day

Journal

JAMAAmerican Medical Association

Published: Oct 4, 1965

There are no references for this article.